KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Long-Term Deferred Tax (2016 - 2026)

Gsk has reported Long-Term Deferred Tax over the past 18 years, most recently at $8.5 billion for Q1 2026.

  • For Q1 2026, Long-Term Deferred Tax rose 5.32% year-over-year to $8.5 billion; the TTM value through Mar 2026 reached $8.5 billion, up 5.32%, while the annual FY2025 figure was $8.7 billion, 0.0% changed from the prior year.
  • Long-Term Deferred Tax for Q1 2026 was $8.5 billion at Gsk, down from $8.7 billion in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $8.8 billion in Q2 2025 and troughed at $421.3 million in Q1 2022.
  • A 5-year average of $7.2 billion and a median of $7.5 billion in 2023 define the central range for Long-Term Deferred Tax.
  • Biggest five-year swings in Long-Term Deferred Tax: tumbled 92.91% in 2022 and later soared 1518.42% in 2023.
  • Year by year, Long-Term Deferred Tax stood at $6.6 billion in 2022, then rose by 13.13% to $7.5 billion in 2023, then increased by 15.52% to $8.7 billion in 2024, then rose by 0.0% to $8.7 billion in 2025, then decreased by 1.96% to $8.5 billion in 2026.
  • Business Quant data shows Long-Term Deferred Tax for GSK at $8.5 billion in Q1 2026, $8.7 billion in Q4 2025, and $8.3 billion in Q3 2025.